RT Book, Section
A1 Reddy, Divya
A1 O’Donnell, Max R.
A2 Jameson, J. Larry
A2 Fauci, Anthony S.
A2 Kasper, Dennis L.
A2 Hauser, Stephen L.
A2 Longo, Dan L.
A2 Loscalzo, Joseph
SR Print(0)
ID 1155968625
T1 Antimycobacterial Agents
T2 Harrison's Principles of Internal Medicine, 20e
YR 2018
FD 2018
PB McGraw-Hill Education
PP New York, NY
SN 9781259644016
LK accesspharmacy.mhmedical.com/content.aspx?aid=1155968625
RD 2024/04/24
AB Agents  used  for  the  treatment  of  mycobacterial  infections,  including  tuberculosis  (TB),  leprosy,  and  infections  due  to  nontuberculous  mycobacteria  (NTM),  are  administered  in  multiple-drug  regimens  for  prolonged  courses.  Currently,  >160  species  of  mycobacteria  have  been  identified,  the  majority  of  which  do  not  cause  disease  in  humans.  While  the  incidence  of  disease  caused  by  Mycobacterium  tuberculosis  has  been  declining  in  the  United  States,  TB  remains  a  leading  cause  of  morbidity  and  mortality  in  developing  countries—particularly  in  sub-Saharan  Africa  and  Asia,  where  the  HIV  epidemic  rages.  Not  only  effective  drug  regimens  are  needed;  without  a  well-organized  infrastructure  for  diagnosis  and  treatment  of  TB,  therapeutic  and  control  efforts  are  severely  hampered  (Chaps.  460  and  462).  Infections  with  NTM  have  gained  in  clinical  prominence  in  the  United  States  and  other  developed  countries.  These  largely  environmental  organisms  often  establish  infection  in  immunocompromised  patients  or  in  persons  with  structural  lung  disease.